Immunology. Therapeutic manipulation of gut flora.
| dc.contributor.author | Shanahan, F | |
| dc.date.accessioned | 2012-02-03T15:12:36Z | |
| dc.date.available | 2012-02-03T15:12:36Z | |
| dc.date.issued | 2012-02-03T15:12:36Z | |
| dc.identifier.citation | Science. 2000 Aug 25;289(5483):1311-2. | en_GB |
| dc.identifier.issn | 0036-8075 (Print) | en_GB |
| dc.identifier.issn | 0036-8075 (Linking) | en_GB |
| dc.identifier.pmid | 10979858 | en_GB |
| dc.identifier.uri | http://hdl.handle.net/10147/209113 | |
| dc.description.abstract | In developed countries as many as two individuals in every thousand suffer from inflammatory bowel disease (ulcerative colitis and Crohn's disease). In his Perspective, Shanahan discusses a new therapeutic approach to treating these conditions in which bacteria normally found in the gut are engineered to produce the anti-inflammatory cytokine interleukin-10 and then are fed as probiotics to mice with these disorders (Steidler et al.). | |
| dc.language.iso | eng | en_GB |
| dc.subject.mesh | Animals | en_GB |
| dc.subject.mesh | Genetic Engineering | en_GB |
| dc.subject.mesh | Humans | en_GB |
| dc.subject.mesh | Immunity, Mucosal | en_GB |
| dc.subject.mesh | Inflammatory Bowel Diseases/*immunology/*therapy | en_GB |
| dc.subject.mesh | Interleukin-10/administration & dosage/*biosynthesis/genetics/immunology | en_GB |
| dc.subject.mesh | Intestinal Mucosa/immunology/microbiology | en_GB |
| dc.subject.mesh | Intestines/immunology/*microbiology | en_GB |
| dc.subject.mesh | Lactococcus lactis/*genetics/immunology/metabolism | en_GB |
| dc.subject.mesh | Mice | en_GB |
| dc.subject.mesh | Probiotics/*therapeutic use | en_GB |
| dc.subject.mesh | Recombinant Proteins/administration & dosage/biosynthesis/immunology | en_GB |
| dc.subject.mesh | T-Lymphocyte Subsets/immunology | en_GB |
| dc.title | Immunology. Therapeutic manipulation of gut flora. | en_GB |
| dc.contributor.department | Department of Medicine, Cork University Hospital, Cork, Ireland. fshanahan@ucc.ie | en_GB |
| dc.identifier.journal | Science (New York, N.Y.) | en_GB |
| dc.description.province | Munster | |
| html.description.abstract | In developed countries as many as two individuals in every thousand suffer from inflammatory bowel disease (ulcerative colitis and Crohn's disease). In his Perspective, Shanahan discusses a new therapeutic approach to treating these conditions in which bacteria normally found in the gut are engineered to produce the anti-inflammatory cytokine interleukin-10 and then are fed as probiotics to mice with these disorders (Steidler et al.). |